Copyright © 2000 by the European Society of Cardiology.
Hotline Editorial
The VA HDL Intervention Trial: clinical implications
a Center for Chronic Disease Outcomes Research, Veterans Affairs Medical Center, Minneapolis, Minnesota, U.S.A.
b Department of Veterans Affairs Cooperative Studies Program Coordinating Center, West Haven, Connecticut, U.S.A.
c Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, U.S.A.
References
- Rubins HB, Robins SJ, Collins D. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol. 1995;75:11961201[CrossRef][Web of Science][Medline]
- Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 1997;17:107113
[Abstract/Free Full Text] - Rubins HB, Robins SJ, Iwane MK. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol an desirable low-density lipoprotein cholesterol. Am J Cardiol. 1993;71:4552[CrossRef][Web of Science][Medline]
- Rubins HB, Robins SJ, Collins D. The Veterans Affairs High-Density Lipoprotein Intervention Trial: Baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol. 1996;78:572575[CrossRef][Web of Science][Medline]
- Rubins HB, Robins SJ, Collins D. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410418
[Abstract/Free Full Text] - Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:10011009
[Abstract/Free Full Text] - N Engl J Med. 1998;339:13491357
[Abstract/Free Full Text] - Wilson PWF, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:11041109
[Abstract/Free Full Text] - Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:14
[Free Full Text] - Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with Gemfibrozil. Experience from the Helsinki Heart Study. Circulation. 1995;92:17791785
[Abstract/Free Full Text] - Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis. 1994;111:161174[CrossRef][Web of Science][Medline]
- Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:20882093
[Abstract/Free Full Text] - DiPalma JR, Thayer WS. Use of niacin as a drug. Annu Rev Nutr. 1991;11:169187[CrossRef][Web of Science][Medline]
- Goldbourt U, Behar S, Reiss-Reicher H. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 1993;71:909915[CrossRef][Web of Science][Medline]
- Grundy SM, Balady GJ, Criqui MH. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on risk reduction. Circulation. 1997;95:16831685
[Free Full Text]
This article has been cited by other articles:
![]() |
T. Fu, D. Mukhopadhyay, N. O. Davidson, and J. Borensztajn The Peroxisome Proliferator-activated Receptor {alpha} (PPAR{alpha}) Agonist Ciprofibrate Inhibits Apolipoprotein B mRNA Editing in Low Density Lipoprotein Receptor-deficient Mice: EFFECTS ON PLASMA LIPOPROTEINS AND THE DEVELOPMENT OF ATHEROSCLEROTIC LESIONS J. Biol. Chem., July 2, 2004; 279(27): 28662 - 28669. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Vohnout Letter to the Editor: Clinical implications of clinical studies: can we compare different subgroups defined a posteriori? Eur. Heart J., May 1, 2001; 22(9): 798 - 798. [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

